Verastem (VSTM) Projected to Post Earnings on Wednesday

Verastem (NASDAQ:VSTM) is anticipated to post its Q4 2025 results after the market closes on Wednesday, March 4th. Analysts expect Verastem to post earnings of ($0.49) per share and revenue of $16.8510 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 4:30 PM ET.

Verastem Price Performance

Shares of Verastem stock opened at $5.90 on Wednesday. The business has a 50 day moving average of $6.82 and a 200 day moving average of $8.30. Verastem has a 52 week low of $4.01 and a 52 week high of $11.24. The company has a market cap of $394.00 million, a PE ratio of -1.46 and a beta of 0.41. The company has a quick ratio of 2.55, a current ratio of 2.58 and a debt-to-equity ratio of 2.06.

Analyst Ratings Changes

Several equities research analysts have recently commented on VSTM shares. Guggenheim reaffirmed a “buy” rating on shares of Verastem in a research report on Tuesday, December 30th. Cantor Fitzgerald raised shares of Verastem to a “strong-buy” rating in a research note on Thursday, October 30th. HC Wainwright initiated coverage on Verastem in a research report on Wednesday, February 4th. They set a “buy” rating and a $18.00 price objective on the stock. Zacks Research downgraded Verastem from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Verastem in a research note on Wednesday, January 21st. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Verastem currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.33.

Insiders Place Their Bets

In related news, CEO Dan Paterson sold 10,321 shares of Verastem stock in a transaction on Monday, January 12th. The stock was sold at an average price of $7.16, for a total value of $73,898.36. Following the completion of the sale, the chief executive officer owned 400,104 shares of the company’s stock, valued at $2,864,744.64. The trade was a 2.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Daniel Calkins sold 5,039 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $7.16, for a total value of $36,079.24. Following the sale, the chief financial officer owned 104,719 shares of the company’s stock, valued at approximately $749,788.04. This trade represents a 4.59% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 29,678 shares of company stock worth $253,405. Company insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Verastem

Several institutional investors have recently made changes to their positions in the business. Rhumbline Advisers grew its position in Verastem by 19.2% during the second quarter. Rhumbline Advisers now owns 59,553 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 9,594 shares during the period. MetLife Investment Management LLC raised its position in Verastem by 10.6% in the fourth quarter. MetLife Investment Management LLC now owns 28,929 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 2,784 shares during the period. Virtus Investment Advisers LLC bought a new stake in shares of Verastem during the 4th quarter valued at $214,000. Quarry LP bought a new stake in shares of Verastem during the 4th quarter valued at $208,000. Finally, Entropy Technologies LP purchased a new stake in shares of Verastem in the 4th quarter worth $161,000. Institutional investors own 88.37% of the company’s stock.

Verastem Company Profile

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.